Submitted by Anonymous (not verified) on 22 October 2025 - 11:30
Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised